Massmedica Technologiesp. z o.o.
Research and experimental development on biotechnology
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2020-01-15
Share capital
1 999 250,00 PLN
Registered address
ul. Chorągwi Pancernej 43, 02-951 Warszawa, Poland
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 19.09kMedianUSD 39.85kAverageUSD 2.31m
Net profit
This companyUSD -5.65kMedianUSD -1.56kAverageUSD -90.58k
Operating costs
This companyUSD 24.67kMedianUSD 56.69kAverageUSD 2.29m
Assets
This companyUSD 331.04kMedianUSD 122.05kAverageUSD 2.73m
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-01-29. Active
97 1090 1014 0000 0001 4417 6756
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 29, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy |
Tenders
No recorded participation in tenders.
Authorized Representatives
Maciej Krzysztof Brykczyński — President of the Management Board
Manner of representation
Each member of the management board represents the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Massmedica S.A. | 39,985 | $540,045.92 | 100% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Marek Stanisław Młodzianowski (64) | Większościowy akcjonariusz jedynego wspólnika |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Omnisepticasp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-05-07 | Address change (Ul. Adama Branickiego 17, 02-972, Warszawa → Ul. Chorągwi Pancernej 43, 02-951, Warszawa) | |
| 2020-01-15 | Entered in the register |
FAQ
The main business activity of Massmedica Technologie focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on January 15, 2020.
The headquarters is located at: ul. Chorągwi Pancernej 43, 02-951 Warszawa.
The share capital of the company is PLN 1,999,250 (approx. $540,046).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $7,038 in 2024, which is an increase of 17.0% compared to 2023.
No, in 2024 the company was not profitable, reporting a net loss of $52,897. For comparison, in 2023 the loss was $47,667, meaning the company increased its loss by 5.4%.
The largest operating cost category falls under depreciation and amortization. This category amounted to $50,979 in 2024, representing 93% of all operating expenses.
Last updated: 2026-10-07